Introduction {#S5}
============

Increasing evidence suggest that tuberculosis (TB) disease may disrupt host metabolism and contribute to subsequent risks of chronic non-communicable diseases (NCDs) ([@R4], [@R6], [@R10]). Importantly, the majority of TB patients reside in low- and middle-income countries where chronic NCDs such as type-2 diabetes (diabetes), acute myocardial infarction (AMI), and stroke are increasingly threatening public health achievements ([@R2]).

Diabetes is a well-established risk factor for TB infection ([@R8]), TB disease, and poor TB treatment outcomes ([@R9]). However, epidemiologic data to support the relationship between TB and risk of NCDs are scarce. *Chlamydia pneumoniae, Helicobacter pylori*, influenza, and HIV are associated with cardiovascular disease risk, likely due to chronic systemic inflammation that can lead to atherosclerotic lesions ([@R3]). However, whether individual-level TB risk factors (e.g., comorbidities, treatment duration, site of infection) increase the risk of post-infection incident NCDs is unknown. Therefore, among a large cohort of patients post-TB treatment, we aimed to estimate the incidence rates of diabetes, AMI, and stroke and to determine characteristics associated with these incident NCDs.

Methods {#S6}
=======

We conducted a cohort study among patients formerly treated for TB disease using data from the Taiwan National Health Insurance Research Database(NHIRD)during2002--2013. NHIRD is maintained by the National Health Research Institute and contains original registration and insurance claim data from the single-payer national health insurance system which covers 99.9% of the Taiwanese population.

Eligible patients included those with non-pediatric active TB disease (≥15 years old for DM study; ≥25 years old for AMI and stroke studies) confirmed by ICD-9 codes (010--018) and prescriptions of anti-TB drugs for ≥28 days within a year. The earliest date of TB diagnosis indicated by ICD-9 codes was defined as the TB date. Patients with ICD-9 diagnoses of diabetes, AMI, or stroke on or before date of TB disease were excluded. Incident diabetes was defined as patients who received anti-diabetes drug prescriptions for ≥28 days within a year and a confirmed diabetes ICD-9 (250.X0 or 250.X2) first indicated ≥2 years after TB date. Incident AMI (ICD-9 410.XX) and stroke (ICD-9 430.XX - 438.XX) were defined by ICD-9 codes and ≥3 out-patient clinic visits or 1 hospitalization indicated ≥1 year after TB date. Other comorbidity characteristics including dyslipidemia, hypertension, overweight, HIV, and chronic kidney diseases (CKD) were determined by ICD-9 codes. We calculated incidence of diabetes, AMI, and stroke using Poisson regression, and proportional hazards regression was used to estimate relative hazards of NCDs incidence. Incidence rates (IR) were presented per 1000 person-years. Patients were censored if they left the insurance system or did not develop diabetes, AMI, or stroke by the end of follow-up (December 2013).

Results {#S7}
=======

During the study period, there were 157,444 patients treated for TB disease and 1315 were \<15 years and excluded. Among adult TB cases, 82.9% (129,453/156,129) patients did not have prior diabetes diagnosis; 98.0% (143,678/146,646) did not have prior history of AMI; and 81.0% (118,774/146,646) did not have prior stroke diagnosis ([Supplemental Material 1](#SD1){ref-type="supplementary-material"}) and were included. Among those without preexisting diabetes, 2479 incident diabetes diagnoses occurred during 643,754 person-years (age-adjusted IR 3.85, 95%CI 3.70--4.01) ([Table 1](#T1){ref-type="table"}). The median time of incident diabetes post TB date was 7 years (IQR 5--9) ([Supplemental Material 2](#SD1){ref-type="supplementary-material"}). In the adjusted model, TB patients with pre-existing dyslipidemia (adjusted hazard ratio \[aHR\] 1.41; 95%CI 1.25--1.58), hypertension (aHR 1.78, 95%CI 1.62--1.94), and overweight (aHR 2.67, 95%CI 1.76--4.03) had increased risk of diabetes post-TB treatment ([Table 2](#T2){ref-type="table"}).

The age-adjusted IR of AMI was 3.26 (95%CI 3.13--3.40), and 16.08 (95%CI 15.76--16.32) for stroke. The median time of incident AMI and stroke post-TB date was 6 years (IQR 3--8) and 6 years (IQR 3--9), respectively. In the adjusted models, factors predictive of incident AMI and stroke included pre-existing dyslipidemia (aHR AMI 1.29, 95%CI 1.17--1.43; aHR stroke 1.20, 95%CI 1.13--1.27), hypertension (aHR AMI 1.70, 95%CI 1.54--1.86; aHR stroke 1.67, 95% CI 1.60--1.75), CKD (aHR AMI 1.86,95%CI 1.65--2.11; aHR stroke 1.26, 95%CI 1.17--1.36), and diabetes (aHR AMI 1.96,95%CI 1.79--2.14; aHR stroke 1.47, 95%CI 1.40--1.54).

Discussion {#S8}
==========

Our preliminary findings suggest that older age, male gender, and traditional pre-existing chronic NCDs are predictive of diabetes, AMI, and stroke incidence post-TB treatment. Although overall TB treatment duration was not predictive of diabetes, AMI, and stroke incidence, we found that patients treated for 7--12 months had higher incidence of NCDs compared to those treated for ≤6 months. Furthermore, our incidence estimation of diabetes, AMI, and stroke were higher when compared to previous Taiwanese national estimates using NHIRD database. For example, the annual age-standardized incidence rate of diabetes was \<1% across Taiwanese population ([@R5]). Additionally, the age and gender-adjusted incidence of AMI was 50.7/100,000 persons in 2015 ([@R7]) and the estimated stroke incidence was 12.3/1000 person-years ([@R1]). Our results highlight the need for studies to determine the impact of TB disease on risk of NCDs; such studies will require substantial follow-up time and a control group without TB disease.
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###### 

Incidence rates of diabetes, acute myocardial infarction (AMI), and stroke among a cohort of patients formerly treated for tuberculosis, Taiwan National Health Insurance Research Database (NHIRD), 2002--2013.

  Characteristics                                          Diabetes      AMI                  Stroke                                          
  -------------------------------------------------------- ------------- -------------------- ------------- ------------------- ------------- ----------------------
  Age group                                                                                                                                   
   15--24                                                  14/55138      0.25 (0.15--0.43)    Excluded      N/A                 Excluded      N/A
   25--44                                                  344/151792    2.27 (2.04--2.52)    68/162616     0.42 (0.33--0.53)   530/159684    3.32 (3.05--3.61)
   45--64                                                  959/179001    5.36 (5.03--5.71)    663/229965    2.88 (2.67--3.11)   2788/211591   13.18 (12.70--13.67)
   ≥65                                                     1162/257823   4.51 (4.26--4.77)    1556/308309   5.05 (4.80--5.30)   6275/225120   27.87 (27.19--28.57)
  Gender                                                                                                                                      
   Female                                                  639/217826    2.93 (2.72--3.17)    490/223450    2.19 (2.01--2.40)   2447/194418   12.59 (12.10--13.09)
   Male                                                    1840/422458   4.36 (4.16--4.56)    1797/474570   3.79 (3.62--3.97)   7146/399157   17.90 (17.49--18.32)
   Unknown                                                 0/3470        N/A                  0/2870        N/A                 0/2820        N/A
  TB site                                                                                                                                     
   Pulmonary                                               2145/547526   3.92 (3.76--4.09)    2001/600655   3.33 (3.19--3.48)   8331/512211   16.26 (15.92--16.62)
   Extrapulmonary                                          320/91256     3.51 (3.14--3.91)    264/94947     2.78 (2.47--3.14)   1206/79812    15.11 (14.28--15.99)
   Miliary                                                 14/4972       2.82 (1.67--4.75)    22/5288       2.74 (2.74--6.32)   56/4372       12.81 (9.86--16.64)
  TB treatment duration                                                                                                                       
   ≤6 months                                               1749/469072   3.73 (3.56--3.91)    1564/504205   3.10 (2.95--3.26)   6698/428522   15.63 (15.26--16.01)
   7--12 months                                            668/159157    4.20 (3.89--4.53)    656/178856    3.67 (3.40--3.96)   2633/152429   17.27 (16.63--17.95)
   \>12 months                                             62/15525      3.99 (3.11--5.12)    67/17829      3.76 (2.96--4.78)   262/15444     16.96 (15.03--19.15)
  Dyslipidemia^[a](#TFN3){ref-type="table-fn"}^                                                                                               
   No                                                      2108/574547   3.67 (3.52--3.83)    1766/599014   2.95 (2.81--3.09)   7900/518986   15.22 (14.89--15.56)
   Yes                                                     371/69207     5.36 (4.84--5.94)    521/101876    5.11 (4.69--5.57)   1693/77409    21.87 (20.85--22.94)
  Hypertension^[a](#TFN3){ref-type="table-fn"}^                                                                                               
   No                                                      1410/448700   3.14 (2.98--3.31)    917/444348    2.06 (1.93--2.20)   4795/415207   11.55 (11.23--11.88)
   Yes                                                     1069/195054   5.48 (5.16--5.82)    1370/256542   5.34 (5.07--5.63)   4798/181188   26.48 (25.74--27.24)
  Overweight^[a](#TFN3){ref-type="table-fn"}^                                                                                                 
   No                                                      2456/641308   3.83 (3.68--3.98)    2276/697646   3.26 (3.13--3.40)   9554/593576   16.10 (15.78--16.42)
   Yes                                                     23/2446       9.40 (6.25--14.15)   11/3244       3.39 (1.88--6.12)   39/2819       13.83 (10.11--18.94)
  HIV^[a](#TFN3){ref-type="table-fn"}^                                                                                                        
   No                                                      2474/639526   3.87 (3.72--4.02)    2276/696710   3.27 (3.14--3.41)   9579/592428   16.17 (15.85--16.50)
   Yes                                                     5/4228        1.18 (0.49--2.84)    8/4180        1.91 (0.96--3.83)   14/3967       3.53 (2.09--5.96)
  CKD^[a](#TFN3){ref-type="table-fn"}^                                                                                                        
   No                                                      2378/612063   3.89 (3.73--4.05)    1985/660103   3.01 (2.88--3.14)   8870/567777   15.62 (15.30--15.95)
   Yes                                                     101/31691     3.19 (2.62--3.87)    302/40787     7.40 (6.62--8.29)   723/28618     25.26 (23.49--27.17)
  Diabetes^[a](#TFN3){ref-type="table-fn"}^                Excluded                                                                           
   No                                                                                         1512/582699   2.60 (2.47--2.73)   7183/502688   14.29 (13.96--14.62)
   Yes                                                                                        775/118191    6.56 (6.11--7.04)   2410/93707    25.72 (24.71--26.77)
  Myocardial infarction^[a](#TFN3){ref-type="table-fn"}^                                      Excluded                                        
   No                                                      2457/637226   3.86 (3.71--4.01)                                      9453/590847   16.00 (15.68--16.32)
   Yes                                                     22/6528       3.37 (2.22--5.12)                                      140/5548      25.23 (21.38--29.78)
  Stroke^[a](#TFN3){ref-type="table-fn"}^                                                                                                     
   No                                                      2133/563277   3.79 (3.63--3.95)    1707/598831   2.85 (2.72--2.99)   Excluded      
   Yes                                                     346/80477     4.30 (3.87--4.78)    580/102059    5.68 (5.24--6.17)                 

Notes:

Abbreviation: AMI - Acute Myocardial Infarction; IR - incidence rate; CI - Confidence Interval; PTY - person time in years.

Comorbidities (i.e., dyslipidemia, hypertension, overweight, HIV, and chronic kidney disease) were diagnosed earlier or at the time of TB diagnosis.

###### 

Adjusted Cox regression model^[a](#TFN6){ref-type="table-fn"}^ to predict post-tuberculosis incident diabetes, acute myocardial infarction (AMI), and stroke, Taiwan National Health Insurance Research Database (NHIRD), 2002--2013.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                          Diabetes\                                       AMI\                                            Stroke\
                                                           aHR^[c](#TFN8){ref-type="table-fn"}^ (95% CI)   aHR^[c](#TFN8){ref-type="table-fn"}^ (95% CI)   aHR^[c](#TFN8){ref-type="table-fn"}^ (95% CI)
  -------------------------------------------------------- ----------------------------------------------- ----------------------------------------------- -----------------------------------------------
  Age group                                                                                                                                                

   15--24                                                  **0.11** (**0**.**07**-**0**.**19**)            Excluded                                        Excluded

   25--44                                                  Ref                                             Ref                                             Ref

   45--64                                                  **1.96** (**1**.**73**-**2**.**23**)            **4.72** (**3**.**67**-**6**.**08**)            **3.11** (**2**.**83**-**3**.**42**)

   ≥65                                                     **1.66** (**1**.**46**-**1**.**90**)            **8.01** (**6**.**24**-**10**.**28**)           **6.57** (**6**.**00**-**7**.**20**)

  Gender                                                                                                                                                   

   Female                                                  Ref                                             Ref                                             Ref

   Male                                                    **1.36** (**1**.**24**-**1**.**49**)            **1.57** (**1**.**42**-**1**.**74**)            **1.28** (**1**.**22**-**1**.**34**)

  TB site                                                                                                                                                  

   Pulmonary                                               Ref                                             Ref                                             Ref

   Extrapulmonary                                          0.93 (0.82--1.04)                               0.90 (0.79--1.02)                               1.00 (0.94--1.07)

   Miliary                                                 0.82 (0.48--1.38)                               1.30 (0.86--1.98)                               0.82 (0.63--1.06)

  TB treatment duration                                                                                                                                    

   ≤6 months                                               Ref                                             Ref                                             Ref

   7--12 months                                            1.05 (0.96--1.14)                               1.09 (0.99--1.19)                               1.03 (0.99--1.08)

   \>12 months                                             0.78 (0.61 -- 1.01)                             1.03 (0.81 -- 1.32)                             0.89 (0.78 -- 1.00)

  Dyslipidemia^[b](#TFN7){ref-type="table-fn"}^                                                                                                            

   No                                                      Ref                                             Ref                                             Ref

   Yes                                                     **1.41** (**1**.**25**-**1**.**58**)            **1.29** (**1**.**17**-**1**.**43**)            **1.20** (**1**.**13**-**1**.**27**)

  Hypertension^[b](#TFN7){ref-type="table-fn"}^                                                                                                            

   No                                                      Ref                                             Ref                                             Ref

   Yes                                                     **1.78** (**1**.**62**-**1**.**94**)            **1.70** (**1**.**54**-**1**.**86**)            **1.67** (**1**.**60**-**1**.**75**)

  Overweight^[b](#TFN7){ref-type="table-fn"}^                                                                                                              

   No                                                      Ref                                             Ref                                             Ref

   Yes                                                     **2.67** (**1**.**76**-**4**.**03**)            1.08 (0.60--1.95)                               0.98 (0.72--1.35)

  HIV^[b](#TFN7){ref-type="table-fn"}^                                                                                                                     

   No                                                      Ref                                             Ref                                             Ref

   Yes                                                     0.44 (0.18--1.06)                               1.81 (0.90--3.64)                               0.62 (0.36--1.04)

  CKD^[b](#TFN7){ref-type="table-fn"}^                                                                                                                     

   No                                                      Ref                                             Ref                                             Ref

   Yes                                                     **0.78** (**0**.**64**-**0**.**96**)            **1.86** (**1**.**65**-**2**.**11**)            **1.26** (**1**.**17**-**1**.**36**)

  Diabetes^[b](#TFN7){ref-type="table-fn"}^                Excluded                                                                                        

   No                                                                                                      Ref                                             Ref

   Yes                                                                                                     **1.96** (**1**.**79**-**2**.**14**)            **1.47** (**1**.**40**-**1**.**54**)

  Myocardial infarction^[b](#TFN7){ref-type="table-fn"}^                                                   Excluded                                        

   No                                                      Ref                                                                                             Ref

   Yes                                                     0.84 (0.55--1.28)                                                                               1.05 (0.89--1.24)

  Stroke^[b](#TFN7){ref-type="table-fn"}^                                                                                                                  Excluded

   No                                                      Ref                                             Ref                                             

   Yes                                                     0.96 (0.85--1.08)                               **1.24** (**1**.**12**-**1**.**37**)            
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviation: AMI - Acute Myocardial Infarction; IQR - interquartile range; CHR - Crude hazard ratio; AHR - Adjusted Hazard Ratio; CI - Confidence Interval; TB - Tuberculosis.

**Bold** indicates statistical significance (two-sided P-value \<0.05).

Proportional hazard assumption was assessed using Schoenfeld's residual and log of negative log curve.

Comorbidities (i.e., dyslipidemia, hypertension, overweight, HIV, and chronic kidney disease) were diagnosed earlier or at the time of TB diagnosis.

Hazard Ratios after adjusting for age, gender, type of TB, anti TB treatment duration, dyslipidemia, hypertension, and chronic kidney disease status.
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